about
Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic StrategiesTargeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.Antibodies are back for thymic attack in cGVHD.Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice.Circulating T follicular helper cells with increased function during chronic graft-versus-host diseaseOrigin and evolution of the T cell repertoire after posttransplantation cyclophosphamide.Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease.B-Cell-Based and Soluble Biomarkers in Body Liquids for Predicting Acute/Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.Pathophysiology of GvHD and Other HSCT-Related Major Complications.Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.TLR7/TLR9- and B Cell Receptor-Signaling Crosstalk: Promotion of Potentially Dangerous B Cells.New answers to old conundrums: what antibodies, exosomes and inflammasomes bring to the conversation. Canadian National Transplant Research Program international summit report.Potential of glycosylation research in graft versus host disease after allogeneic hematopoietic stem cell transplantation.B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality.Mechanistic approaches for the prevention and treatment of chronic GVHD.Novel targets in the treatment of chronic graft-versus-host disease.Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation-pathophysiology, diagnostics and treatment.Mesenchymal Stem Cells May Ameliorate Nephrotic Syndrome Post-Allogeneic Hematopoietic Stem Cell Transplantation-Case ReportProtective Effect of Rituximab in Chronic Graft-Versus-Host Disease Occurrence in Allogeneic Transplant patients with Epstein Barr Virus Viremia.An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD.New and emerging therapies for acute and chronic graft versus host disease.Patients with Treatment-Requiring Chronic Graft versus Host Disease after Allogeneic Stem Cell Transplantation Have Altered Metabolic Profiles due to the Disease and Immunosuppressive Therapy: Potential Implication for Biomarkers.Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease.Biomarkers for post-transplantation outcomes.Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD.Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects
P2860
Q26751959-73642056-0338-4A48-83B3-89DB91752C6AQ36851405-FCC13E1E-A4DC-424E-A3FC-C9738B0BED34Q36876960-DA7146C7-0D25-4B92-B42C-921A87FB575DQ36876981-24DA002C-630C-4D26-821C-AF987DA4EEBDQ36920466-E8EC86CE-0435-4062-973F-3124A80B66E3Q36921230-32CF4D63-898D-403D-999C-B068D1A2DA74Q37241480-B14A581A-5E82-4A3A-85D6-08AB7124D4E1Q37587724-51A09CD8-FAFF-4CF3-ABF4-4557392C243CQ37710572-C8C08575-9568-4119-BD3B-59BD0E7E1001Q38392246-514CB784-2EC4-4DE8-B0EE-F63F3C143D46Q38656329-34B4DB4F-4BE4-49C5-B622-A5171C91CB3EQ38668025-2925FF2C-2435-472F-918C-D5BD1DE790A5Q38753771-CC0D52A3-84AE-4486-8770-099991C0C7B6Q38798545-A2ECBF96-33DE-4601-A500-0C725C917989Q39002166-7CEDDA2C-0FC2-4090-95F2-11D8BBD1C34FQ39023963-EA0A49E1-78B0-4DD4-BFA7-0D9DFD587F00Q39437352-9D530EDE-42FC-40CB-9D56-4A859F7BF09DQ40122845-E44487F0-632B-42EF-B49C-CC7CE2294808Q40354412-8D719F22-AA7F-4663-93CB-D5694D1A1FE9Q40385568-E4475EA5-DC6B-461F-8F2F-E6449DD7293CQ41417888-9ABF9BB3-BB38-452C-AC95-CD8800C98AC3Q45325606-5B95AC6A-1E3A-47BC-B243-19D9148D12C6Q47709978-8B2B11BB-CAF8-406D-87C5-9A15587739B2Q49238507-C281C8AB-E471-47D4-9348-3D4FDFDBB81DQ49464975-A7A2E30B-F4E3-41D8-98AA-81F2ACAA4842Q49630800-64B3850A-F0CE-4497-BAA2-F8F470FC45B4Q52603913-997BD608-9587-4498-8FFD-2734989E0C9BQ52897641-57F27857-E807-487A-8F96-ABAA6569BA6DQ57817494-D1FE7CD5-3B1E-4AB4-AC9C-0EF9B9D4975F
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Aberrant B-cell homeostasis in chronic GVHD
@ast
Aberrant B-cell homeostasis in chronic GVHD
@en
type
label
Aberrant B-cell homeostasis in chronic GVHD
@ast
Aberrant B-cell homeostasis in chronic GVHD
@en
prefLabel
Aberrant B-cell homeostasis in chronic GVHD
@ast
Aberrant B-cell homeostasis in chronic GVHD
@en
P2860
P1433
P1476
Aberrant B-cell homeostasis in chronic GVHD
@en
P2093
Jerome Ritz
P2860
P304
P356
10.1182/BLOOD-2014-12-567834
P407
P577
2015-02-02T00:00:00Z